Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis

Frontiers in Cellular Neuroscience

Volumn 7, Issue DEC, 2013, Pages

  Gerber, Yannick N ^a,b   Privat, Alain ^a   Perrin, Florence E ^a,b,c  

^a Montpellier University Medical Center   (France)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c UNIV MONTPELLIER   (France)

Author keywords

ALS; GK11; Locomotion; NMDA receptor antagonist; Survival

Indexed keywords

GACYCLIDINE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; LOCOMOTION; MOTOR ACTIVITY; MOUSE; NONHUMAN; OPEN FIELD TEST; SURVIVAL; TRANSGENIC MOUSE; WALKING;

EID: 84891521369     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2013.00280     Document Type: Article

References (47)

1. Bhagat, Y. A., Obenaus, A., Hamilton, M. G., Mikler, J., and Kendall, E. J. (2005). Neuroprotection from soman-induced seizures in the rodent: evaluation with diffusion- and T2-weighted magnetic resonance imaging. Neurotoxicology 26, 1001-1013. doi: 10.1016/j.neuro.2005.04.006
2. Bogaert, E., d'Ydewalle, C., and Van Den Bosch, L. (2010). Amyotrophic lateral sclerosis and excitotoxicity: from pathological mechanism to therapeutic target. CNS Neurol. Disord. Drug Targets 9, 297-304. doi: 10.2174/187152710791292576
3. Carriedo, S. G., Yin, H. Z., and Weiss, J. H. (1996). Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J. Neurosci. 16, 4069-4079.
4. Chang, P. K., Verbich, D., and McKinney, R. A. (2012). AMPA receptors as drug targets in neurological disease-advantages, caveats, and future outlook. Eur. J. Neurosci. 35, 1908-1916. doi: 10.1111/j.1460-9568.2012. 08165.x
5. Cheah, B. C., Vucic, S., Krishnan, A. V., and Kiernan, M. C. (2010). Riluzole, neuro-protection and amyotrophic lateral sclerosis. Curr. Med. Chem. 17, 1942-1199. doi: 10.2174/092986710791163939
6. Cifra, A., Mazzone, G. L., and Nistri, A. (2013). Riluzole: what it does to spinal and brainstem neurons and how it does it. Neuroscientist 19, 137-144. doi: 10.1177/1073858412444932
7. Clarke, K. A., and Still, J. (1999). Gait analysis in the mouse. Physiol. Behav. 66, 723-729. doi: 10.1016/S0031-9384(98)00343-6
8. Corona, J. C., Tovar-y-Romo, L. B., and Tapia, R. (2007). Glutamate excitotoxic-ity and therapeutic targets for amyotrophic lateral sclerosis. Expert Opin. Ther. Ta r g e t s 11, 1415-1428. doi: 10.1517/14728222.11.11.1415
9. De Carvalho, M., Pinto, S., Costa, J., Evangelista, T., Ohana, B., and Pinto, A. (2010). A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 11, 456-460. doi: 10.3109/17482968.2010.498521
10. Feldblum, S., Arnaud, S., Simon, M., Rabin, O., and D'Arbigny, P. (2000). Efficacy of a new neuroprotective agent, gacyclidine, in a model of rat spinal cord injury. J. Neurotrauma 17, 1079-1093. doi: 10.1089/neu.2000.17.1079
11. Foran, E., and Trotti, D. (2009). Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid. Redox Signal. 11, 1587-1602. doi: 10.1089/ars.2009.2444
12. Gaviria, M., Privat, A., d'Arbigny, P., Kamenka, J., Haton, H., and Ohanna, F. (2000a). Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats. Brain Res. 874, 200-209. doi: 10.1016/S0006-8993(00)02581-6
13. Gaviria, M., Privat, A., d'Arbigny, P., Kamenka, J. M., Haton, H., and Ohanna, F. (2000b). Neuroprotective effects of gacyclidine after experimental photochemical spinal cord lesion in adult rats: dose-window and time-window effects. J. Neurotrauma 17, 19-30. doi: 10.1089/neu.2000.17.19
14. Gerardo-Nava, J., Mayorenko, I. I., Grehl, T., Steinbusch, H. W., Weis, J., and Brook, G. A. (2013). Differential pattern of neuroprotection in lumbar, cervical and thoracic spinal cord segments in an organotypic rat model of glutamate-induced excitotoxicity. J. Chem. Neuroanat. 53, 11-17. doi: 10.1016/j.jchemneu.2013.09.007
15. Gerber, Y. N., Sabourin, J. C., Rabano, M., Vivanco, M., and Perrin, F. E. (2012a). Early functional deficit and microglial disturbances in a mouse model of amyotrophic lateral sclerosis. PLoS ONE 7:e36000. doi: 10.1371/jour-nal.pone.0036000
16. Gerber, Y. N., Sabourin, J. C., Hugnot, J. P., and Perrin, F. E. (2012b). Unlike physical exercise, modified environment increases the lifespan of SOD1G93A mice however both conditions induce cellular changes. PLoS ONE 7:e45503. doi: 10.1371/journal.pone.0045503
17. Gibson, S. B., and Bromberg, M. B. (2012). Amyotrophic lateral sclerosis: drug therapy from the bench to the bedside. Semin. Neurol. 32, 173-178. doi: 10.1055/s-0032-1329193
18. Gurney, M. E., Cutting, F. B., Zhai, P., Doble, A., Taylor, C. P., Andrus, P. K., et al. (1996). Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39, 147-157. doi: 10.1002/ana.410390203
19. Heath, P. R., and Shaw, P. J. (2002). Update on the glutamatergic neurotransmit-ter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 26, 438-458. doi: 10.1002/mus.10186
20. Heiman-Patterson, T. D., Deitch, J. S., Blankenhorn, E. P., Erwin, K. L., Perreault, M. J., Alexander, B. K., et al. (2005). Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 236, 1-7. doi: 10.1016/j.jns.2005.02.006
21. Hirbec, H., Gaviria, M., and Vignon, J. (2001). Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor. CNS Drug Rev. 7, 172-198. doi: 10.1111/j.1527-3458.2001.tb00194.x
22. Jin, L. J., Schlesinger, F., Song, Y. P., Dengler, R., and Krampfl, K. (2010). The interaction of the neuroprotective compounds riluzole and phenobarbital with AMPA-type glutamate receptors: a patch-clamp study. Pharmacology 85, 54-62. doi: 10.1159/000268641
23. Joo, I. S., Hwang, D. H., Seok, J. I., Shin, S. K., and Kim, S. U. (2007). Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Clin. Neurol. 3, 181-186. doi: 10.3988/jcn.2007.3.4.181
24. Kawahara, Y., Sun, H., Ito, K., Hideyama, T., Aoki, M., Sobue, G., et al. (2006). Underediting of GluR2 mRNA, a neuronal death inducing molecular change in sporadic ALS, does not occur in motor neurons in ALS1 or SBMA. Neurosci. Res. 54, 11-14. doi: 10.1016/j.neures.2005.09.006
25. Kouyoumdjian, P., Lonjon, N., Prieto, M., Haton, H., Privat, A., Asencio, G., et al. (2009). A remotely controlled model of spinal cord compression injury in mice: toward real-time analysis. J. Neurosurg. Spine 11, 461-470. doi: 10.3171/2009.4.SPINE0979
26. Leitner, M. M., and Lutz, S. C. (2009). Working With ALS Mice in Guidelines for Preclinical Testing and Colony Management. Bar Harbor, ME: The Jackson Laboratory; Cambridge, MA: Prize 4Life, 1-21.
27. Lepeintre, J. F., D'Arbigny, P., Mathe, J. F., Vigue, B., Loubert, G., Delcour, J., et al. (2004). Neuroprotective effect of gacyclidine. A multicenter double-blind pilot trial in patients with acute traumatic brain injury. Neuro-Chirurgie 50(2-3 Pt 1), 83-95.
28. Levine, T. D., Bowser, R., Hank, N., and Saperstein, D. A. (2010). Pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph. Lateral Scler. 11, 514-519. doi: 10.3109/17482968.2010.513052
29. Lonjon, N., Kouyoumdjian, P., Prieto, M., Bauchet, L., Haton, H., Gaviria, M., et al. (2010). Early functional outcomes and histological analysis after spinal cord compression injury in rats. J. Neurosurg. Spine 12, 106-113. doi: 10.3171/2009.7.SPINE0989
30. Loscher, W., and Honack, D. (1992). The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrener-gic systems. Eur. J. Pharmacol. 215, 199-208. doi: 10.1016/0014-2999(92) 90029-4
31. Matsuoka, T., Sumiyoshi, T., Tanaka, K., Tsunoda, M., Uehara, T., Itoh, H., et al. (2005). NC-1900, an arginine-vasopressin analogue, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: therapeutic implications for schizophrenia. Brain Res. 1053, 131-136. doi: 10.1016/j.brainres. 2005.06.035
32. Mehta, A., Prabhakar, M., Kumar, P., Deshmukh, R., and Sharma, P. L. (2013). Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur. J. Pharmacol. 698, 6-18. doi: 10.1016/j.ejphar.2012.10.032
33. Miller, R. G., Mitchell, J. D., and Moore, D. H. (2012). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 3, CD001447. doi: 10.1002/14651858.CD001447.pub3
34. Naumenko, N., Pollari, E., Kurronen, A., Giniatullina, R., Shakirzyanova, A., Magga, J., et al. (2011). Gender-specific mechanism of synaptic impairment and its prevention by GCSF in a mouse model of ALS. Front. Cell. Neurosci. 5:26. doi: 10.3389/fncel.2011.00026
35. Olney, J. W. (1989). Glutamate, a neurotoxic transmitter. J. Child Neurol. 4, 218-226. doi: 10.1177/088307388900400315
36. Plaitakis, A., and Constantakakis, E. (1993). Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in amy-otrophic lateral sclerosis. Brain Res. Bull. 30, 381-386. doi: 10.1016/0361-9230(93)90269-H
37. Robberecht, W., and Philips, T. (2013). The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 14, 248-264. doi: 10.1038/nrn3430
38. Rogawski, M. A. (2011). Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 11, 56-63. doi: 10.5698/1535-7511-11.2.56
39. Solomon, J. A., Tarnopolsky, M. A., and Hamadeh, M. J. (2011). One universal common endpoint in mouse models of amyotrophic lateral sclerosis. PLoS ONE 6:e20582. doi: 10.1371/journal.pone.0020582
40. Spalloni, A., Nutini, M., and Longone, P. (2013). Role of the N-methyl-d-aspartate receptors complex in amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1832, 312-322. doi: 10.1016/j.bbadis.2012.11.013
41. Tadie, M., Gaviria, M., Mathe, J.-F., Menthonenex, P., Loubert, G., Lagarrigue, J., et al. (2003). Early care and treatment with a neuroprotective drug, gacyclidine, in patients with acute spinal cord injury. Rachis 15, 363-376.
42. Turner, M. R., Hardiman, O., Benatar, M., Brooks, B. R., Chio, A., de Carvalho, M., et al. (2013). Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 12, 310-322. doi: 10.1016/S1474-4422(13)70036-X
43. Van Den Bosch, L., Vandenberghe, W., Klaassen, H., Van Houtte, E., and Robberecht, W. (2000). Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J. Neurol. Sci. 180, 29-34. doi: 10.1016/S0022-510X(00)00414-7
44. Vandame, D., Desmadryl, G., Becerril Ortega, J., Teigell, M., Crouzin, N., Buisson, A., et al. (2007). Comparison of the pharmacological properties of GK11 and MK801, two NMDA receptor antagonists: towards an explanation for the lack of intrinsic neurotoxicity of GK11. J. Neurochem. 103, 1682-1696. doi: 10.1111/j.1471-4159.2007.04925.x
45. Vandame, D., Ulmann, L., Teigell, M., Cappelini-Prieto, M., Vignon, J., Privat, A., et al. (2013). Development of NMDARs antagonists with reduced neuro-toxic side effects: a study on GK11. PLoS ONE 8:e81004. doi: 10.1371/jour-nal.pone.0081004
46. Wang, R., and Zhang, D. (2005). Memantine prolongs survival in an amy-otrophic lateral sclerosis mouse model. Eur. J. Neurosci. 22, 2376-2380. doi: 10.1111/j.1460-9568.2005.04431.x
47. Wolf, M. E., and Khansa, M. R. (1991). Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res. 562, 164-168. doi: 10.1016/0006-8993(91)91202-C